Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04626 (erbB-2)
 5,251 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The psoralen analogs 8-methoxypsoralen (8-MOP) and 4,5',8-trimethylpsoralen (TMP), in combination with ultraviolet light (UVA, 320-400 nm), are potent modulators of epidermal cell growth and differentiation and are commonly used in photochemotherapy of psoriasis and vitiligo. We have used KB cells, a human epithelial cell line, to examine the mechanism of action of these compounds. In KB cells, 8-MOP was found to bind to specific, saturable receptor sites. Binding of [3H]-8-MOP to its receptor was inhibited by TMP as well as psoralen. We found that binding of these analogs to the cells followed by UVA light treatment was associated with inhibition of epidermal growth factor (EGF) receptor binding. Inhibition of EGF binding was temperature dependent, occurred immediately following UVA light exposure, and appeared to be due to a decrease in the number of EGF receptors. In KB cells, 125I-labeled EGF surface receptor binding is followed by its rapid internalization and degradation. We found that photoactivated psoralens also inhibited internalization of 125I-EGF, but had no apparent effect on EGF metabolism. These data indicate that the cell surface membrane may be an important target for the photoactivated psoralens. In addition, since photoactivated psoralens regulate cell proliferation, the interaction of these compounds with EGF receptor function may underlie their biological activity.
 ...
PMID:Psoralen binding and inhibition of epidermal growth factor binding by psoralen/ultraviolet light (PUVA) in human epithelial cells. 184 71